MARKET

SESN

SESN

Sesen Bio, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9084
-0.0204
-2.20%
After Hours: 0.9188 +0.0104 +1.14% 19:58 09/17 EDT
OPEN
0.9190
PREV CLOSE
0.9288
HIGH
0.9499
LOW
0.9084
VOLUME
21.49M
TURNOVER
--
52 WEEK HIGH
6.04
52 WEEK LOW
0.7000
MARKET CAP
178.05M
P/E (TTM)
-1.1304
1D
5D
1M
3M
1Y
5Y
Sesen Update
New York, New York--(Newsfile Corp. - September 17, 2021) -  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN) and reminds investors of the Octo...
Newsfile Corp · 11h ago
Sesen Bio News: Berger Montague Investigates Securities Fraud Allegations Against Sesen Bio, Inc. (SESN); Lead Plaintiff Deadline is October 18, 2021
Philadelphia, Pennsylvania--(Newsfile Corp. - September 17, 2021) - Berger Montague is investigating securities fraud allegations against Sesen Bio, Inc. ("Sesen" or the "Company"). The Firm is investigating these claims on behalf of investors who purchase...
Newsfile · 16h ago
Sesen Shareholder Notice
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sesen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 15, 2021) - Faruqi & Faruqi, LLP, a leadi...
Newsfile · 2d ago
Berman Tabacco Announces Upcoming Lead Plaintiff Deadline for Investors with Significant Losses in Sesen Bio, Inc. (SESN)
Boston, Massachusetts--(Newsfile Corp. - September 14, 2021) - The Massachusetts office of Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Sesen Bio, Inc. ("Sesen Bio" or the "Company") (...
Newsfile Corp · 3d ago
Sesen Deadline Alert
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sesen To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - September 13, 2021) - Faruqi & Faruqi, LLP, a leadi...
Newsfile · 4d ago
Sesen Bio Shares Spike Higher; Co Issues 8K Filing Saying Preliminary Results From Interim Analysis Of 12 Patients In NCI Trial Being Presented
https://www.sec.gov/ix?doc=/Archives/edgar/data/1485003/000148500321000188/sesn-20210910.htm
Benzinga · 09/10 16:39
BeyondSpring sheds over 10% recording second biggest loss for the year
BeyondSpring (BYSI -13.0%) has lost more than a tenth of its value to post its biggest intra-day drop since early August as the shares of small-cap biopharma company look set
Seekingalpha · 09/07 17:25
SESEN DEADLINE ALERT: Faruqi & Faruqi LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Sesen To Contact Him Directly To Discuss Their Options
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN) and reminds investors of the October 18, 2021 deadline to seek the role of lead plaintiff in a...
GlobeNewswire · 09/05 12:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SESN. Analyze the recent business situations of Sesen Bio, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SESN stock price target is 2.250 with a high estimate of 3.000 and a low estimate of 1.500.
EPS
Institutional Holdings
Institutions: 122
Institutional Holdings: 77.10M
% Owned: 39.34%
Shares Outstanding: 196.00M
TypeInstitutionsShares
Increased
31
28.70M
New
43
4.64M
Decreased
21
4.45M
Sold Out
13
2.80M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Non-Executive Chairman/Independent Director
Jay Duker
President/Chief Executive Officer/Director
Thomas Cannell
Chief Financial Officer/Treasurer
Monica Forbes
Chief Technology Officer
Glen MacDonald
Chief Accounting Officer/Controller
Elly Ryu
General Counsel/Secretary
Mark Sullivan
Director
Peter Honig
Director
Michael Jewett
Independent Director
Carrie Bourdow
Independent Director
Jane Henderson
Independent Director
Jason Keyes
No Data
About SESN
Sesen Bio, Inc., formerly Eleven Biotherapeutics, Inc., is a late-stage clinical company that provides targeted protein therapeutics (TPT) platform. The Company is focused on developing antibody-drug conjugate (ADC) therapies for the treatment of cancer. Its product pipeline includes Vicinium, Vicinium in combination with checkpoint inhibator, durvalumab, and VB6-845d. The Company’s lead program, Vicinium, is a fusion protein in Phase III development for the treatment of non-muscle invasive bladder cancer (NMIBC). It targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent cytotoxin, Pseudomonas Exotoxin A (ETA) directly to cancer cells.

Webull offers kinds of Sesen Bio Inc stock information, including NASDAQ:SESN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SESN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SESN stock methods without spending real money on the virtual paper trading platform.